Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.66 Million EUR | -92.34% |
| 2022 | -11.65 Million EUR | 75.64% |
| 2021 | -47.82 Million EUR | -249.29% |
| 2020 | -13.69 Million EUR | 49.39% |
| 2019 | -27.05 Million EUR | -625.71% |
| 2018 | 5.14 Million EUR | 112.87% |
| 2017 | -39.98 Million EUR | -628.11% |
| 2016 | 7.57 Million EUR | 170.28% |
| 2015 | -10.77 Million EUR | 46.05% |
| 2014 | -19.96 Million EUR | -614.86% |
| 2013 | -2.79 Million EUR | 17.51% |
| 2012 | -3.38 Million EUR | 55.27% |
| 2011 | -7.57 Million EUR | 44.7% |
| 2010 | -13.69 Million EUR | 11.88% |
| 2009 | -15.53 Million EUR | -41.15% |
| 2008 | -11 Million EUR | -21.06% |
| 2007 | -9.09 Million EUR | -25.58% |
| 2006 | -7.23 Million EUR | -12.84% |
| 2005 | -6.41 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.15 Million EUR | -114.45% |
| 2024 Q2 | -13.15 Million EUR | 0.0% |
| 2023 Q4 | -6.13 Million EUR | 0.0% |
| 2023 Q3 | -6.13 Million EUR | -16.79% |
| 2023 Q1 | -199.5 Thousand EUR | 99.31% |
| 2023 FY | -22.4 Million EUR | -92.34% |
| 2023 Q2 | -5.25 Million EUR | -2533.08% |
| 2022 FY | -11.65 Million EUR | 75.64% |
| 2022 Q1 | 4.24 Million EUR | 113.74% |
| 2022 Q2 | 4.17 Million EUR | -1.68% |
| 2022 Q3 | -12.45 Million EUR | -398.42% |
| 2022 Q4 | -28.8 Million EUR | -131.19% |
| 2021 Q1 | -10.26 Million EUR | 41.02% |
| 2021 FY | -47.82 Million EUR | -249.29% |
| 2021 Q3 | -13.64 Million EUR | 48.67% |
| 2021 Q2 | -26.57 Million EUR | -158.81% |
| 2021 Q4 | -30.9 Million EUR | -126.5% |
| 2020 FY | -13.69 Million EUR | 49.39% |
| 2020 Q1 | -4.17 Million EUR | 89.93% |
| 2020 Q4 | -17.41 Million EUR | -241.45% |
| 2020 Q3 | -5.09 Million EUR | 68.42% |
| 2020 Q2 | -16.14 Million EUR | -286.87% |
| 2019 Q2 | 5.7 Million EUR | 20.75% |
| 2019 Q3 | -18.25 Million EUR | -419.74% |
| 2019 Q4 | -41.45 Million EUR | -127.1% |
| 2019 FY | -27.05 Million EUR | -625.71% |
| 2019 Q1 | 4.72 Million EUR | -52.83% |
| 2018 Q1 | -7.45 Million EUR | 31.49% |
| 2018 FY | 5.14 Million EUR | 112.87% |
| 2018 Q4 | 10.02 Million EUR | 0.0% |
| 2018 Q3 | 10.02 Million EUR | 234.53% |
| 2018 Q2 | -7.45 Million EUR | 0.0% |
| 2017 Q1 | -9.11 Million EUR | -273.66% |
| 2017 FY | -39.98 Million EUR | -628.11% |
| 2017 Q4 | -10.87 Million EUR | 0.0% |
| 2017 Q3 | -10.87 Million EUR | -19.31% |
| 2017 Q2 | -9.11 Million EUR | 0.0% |
| 2016 Q2 | -1.46 Million EUR | 0.0% |
| 2016 FY | 7.57 Million EUR | 170.28% |
| 2016 Q4 | 5.24 Million EUR | 0.0% |
| 2016 Q3 | 5.24 Million EUR | 458.66% |
| 2016 Q1 | -1.46 Million EUR | -4342.03% |
| 2015 Q1 | -5.42 Million EUR | 0.57% |
| 2015 FY | -10.77 Million EUR | 46.05% |
| 2015 Q2 | -5.42 Million EUR | 0.0% |
| 2015 Q4 | 34.5 Thousand EUR | 0.0% |
| 2015 Q3 | 34.5 Thousand EUR | 100.64% |
| 2014 Q3 | -5.45 Million EUR | -20.33% |
| 2014 Q1 | -4.53 Million EUR | -1375.9% |
| 2014 Q2 | -4.53 Million EUR | 0.0% |
| 2014 Q4 | -5.45 Million EUR | 0.0% |
| 2014 FY | -19.96 Million EUR | -614.86% |
| 2013 Q3 | -307 Thousand EUR | 71.78% |
| 2013 Q1 | -1.08 Million EUR | -84.09% |
| 2013 FY | -2.79 Million EUR | 17.51% |
| 2013 Q4 | -307 Thousand EUR | 0.0% |
| 2013 Q2 | -1.08 Million EUR | 0.0% |
| 2012 Q4 | -591 Thousand EUR | 0.0% |
| 2012 FY | -3.38 Million EUR | 55.27% |
| 2012 Q3 | -591 Thousand EUR | 0.0% |
| 2011 FY | -7.57 Million EUR | 44.7% |
| 2010 FY | -13.69 Million EUR | 11.88% |
| 2009 FY | -15.53 Million EUR | -41.15% |
| 2008 FY | -11 Million EUR | -21.06% |
| 2007 FY | -9.09 Million EUR | -25.58% |
| 2006 FY | -7.23 Million EUR | -12.84% |
| 2005 FY | -6.41 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -271.307% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 90.054% |
| Adocia SA | -17.62 Million EUR | 28.107% |
| Aelis Farma SA | -6.46 Million EUR | -96.084% |
| Biophytis S.A. | -14.33 Million EUR | 11.61% |
| Advicenne S.A. | -6.45 Million EUR | -96.206% |
| genOway Société anonyme | 2.06 Million EUR | 713.423% |
| IntegraGen SA | -183.77 Thousand EUR | -6793.944% |
| Medesis Pharma S.A. | -4.22 Million EUR | -199.55% |
| Neovacs S.A. | -6.9 Million EUR | -83.408% |
| NFL Biosciences SA | -4.43 Million EUR | -185.955% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -1527.91% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -303.824% |
| Sensorion SA | -22.31 Million EUR | 43.215% |
| Theranexus Société Anonyme | -7.64 Million EUR | -65.745% |
| TME Pharma N.V. | -5.62 Million EUR | -125.267% |
| Valbiotis SA | -7.16 Million EUR | -76.941% |
| TheraVet SA | -2.17 Million EUR | -482.454% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 37.554% |
| argenx SE | -417.15 Million EUR | 96.963% |
| BioSenic S.A. | -7.04 Million EUR | -79.957% |
| Celyad Oncology SA | -8.45 Million EUR | -49.805% |
| DBV Technologies S.A. | -85.24 Million EUR | 85.138% |
| Galapagos NV | -88.26 Million EUR | 85.646% |
| Genfit S.A. | -26.58 Million EUR | 52.336% |
| GeNeuro SA | -14.35 Million EUR | 11.759% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 20.784% |
| Inventiva S.A. | -102.7 Million EUR | 87.665% |
| MaaT Pharma SA | -19.94 Million EUR | 36.474% |
| MedinCell S.A. | -20.97 Million EUR | 39.605% |
| Nanobiotix S.A. | -26.77 Million EUR | 52.691% |
| Onward Medical N.V. | -35.46 Million EUR | 64.275% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -178.489% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 44.884% |
| Oxurion NV | -12.11 Million EUR | -4.616% |
| Pharming Group N.V. | -4.87 Million EUR | -159.635% |
| Poxel S.A. | -28.76 Million EUR | 55.955% |
| GenSight Biologics S.A. | -29.69 Million EUR | 57.338% |
| Transgene SA | -30.01 Million EUR | 57.787% |
| Financière de Tubize SA | -2.14 Million EUR | -490.912% |
| UCB SA | 604 Million EUR | 102.098% |
| Valneva SE | -82.08 Million EUR | 84.566% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 56.067% |